Hygene Pharma Semaglutide and What the Evidence Says

What the trial data actually established about semaglutide

The case for semaglutide as a weight-management medicine rests on the STEP clinical programme, specifically STEP 1, which was published in the New England Journal of Medicine. Over 68 weeks, adults with obesity or overweight who received semaglutide 2.4mg weekly alongside lifestyle guidance lost an average of around 15% of their body weight, compared with roughly 2.4% in the placebo group. That is a meaningful difference, and it is the foundation on which the MHRA granted the UK licence for Wegovy.

The important word there is licence. Those results were generated using pharmaceutical-grade semaglutide produced under tightly controlled manufacturing conditions, then assessed by regulators before any pen reached a patient. The STEP programme studied Wegovy as a pharmaceutical product, not a generic, not a compounded version, not a product labelled by a third-party supplier. When people search for Hygene Pharma semaglutide, they are often hoping the active ingredient is the same regardless of brand. It is a reasonable instinct, but it misses the point of pharmaceutical regulation: it is not only the molecule that matters, it is the purity, the concentration accuracy, the sterility, and the cold-chain integrity of every pen.

NICE reviewed this evidence and recommended semaglutide for eligible adults under technology appraisal TA875. That recommendation applies specifically to licensed Wegovy within a managed clinical pathway, not to semaglutide from unverified sources.

Why Hygene Pharma semaglutide sits outside the legal framework

Hygene Pharma is not a name that appears in the MHRA's register of approved UK medicines, and semaglutide sold under that label does not hold a UK marketing authorisation for weight management. That matters for a practical reason: without an authorisation, there is no regulatory obligation on the manufacturer to demonstrate consistent potency, sterility or correct dosing. A pen that looks identical to Wegovy may contain less active ingredient than stated, more, a contaminant, or (as the MHRA found with seized counterfeit pens) insulin instead of semaglutide, with potentially life-threatening consequences.

The MHRA's ongoing enforcement work gives some context to the scale of this. Large seizures of fake and illegally traded weight-loss pens have been recorded, and the agency has urged the public not to buy these medicines from social-media sellers, unregistered websites, or suppliers who offer them without a prescription. You can check whether any online pharmacy is properly registered in under a minute by searching the GPhC pharmacy register, a legitimate supplier will appear there with a premises registration number you can verify independently. That habit alone filters out a large proportion of unsafe sources.

If you want to read more about how semaglutide works as a licensed treatment, our semaglutide overview covers the mechanism, the licensed schedule and what clinical assessment looks like in practice.

Eligibility, access and the clinical assessment that protects you

Wegovy is a prescription-only medicine for good reason. Semaglutide affects gastric emptying, appetite signalling and blood-sugar regulation, and it interacts with a patient's existing conditions and medicines in ways a prescriber needs to assess individually. The licensed criteria require a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. That assessment is not a bureaucratic hurdle, it is the step that catches contraindications, identifies people who need closer monitoring, and ensures the starting dose is appropriate.

On the NHS, access to Wegovy follows the criteria set out in NICE TA875, which requires treatment within a specialist weight management service for a maximum of two years. Waiting lists are commonly long, and not everyone meets the current NHS threshold. Private treatment through a GPhC-registered pharmacy is the alternative for people who want to start sooner or who fall outside the NHS criteria, and patients in Scotland may find our guide to accessing Wegovy in Edinburgh a useful starting point for understanding local options, but the clinical assessment remains equally important whichever route you take. Our Wegovy cost and pricing page explains what a legitimate private prescription typically includes and why the full cost of clinical oversight matters more than the headline price of a pen.

If you are comparing semaglutide with other licensed options, our weight-loss treatments overview sets out the licensed landscape clearly, including tirzepatide (Mounjaro), which works on two gut-hormone receptors rather than one.

Reporting concerns and finding a safe route forward

If you have already purchased semaglutide from an unverified source, or if you are unsure whether a product you have received is genuine, the MHRA's Yellow Card scheme allows you to report suspected counterfeit or substandard medicines, and doing so genuinely helps protect other people. Stop using any product you have doubts about and speak to a pharmacist or your GP.

For anyone whose search for Hygene Pharma semaglutide was really a search for a safe, legitimate way to access semaglutide for weight loss, the answer is a clinical consultation with a registered prescriber. Our prescribers at nume review every consultation the same day, a real clinician reads your answers, not automated software. If semaglutide is clinically appropriate for you, a prescription follows. If another medicine is a better fit, they will say so. You can speak to our prescribers through our free consultation page.